CORDIS
EU research results

CORDIS

English EN
Induced pluripotent stem cell-based therapy for spinal regeneration

Induced pluripotent stem cell-based therapy for spinal regeneration

Objective

Low back pain (LBP) is a leading cause of disability and morbidity worldwide. It is widely accepted that a major contributor to LBP is intervertebral disc degeneration (IDD). IDD account for at least 40% (~280 million) of all LBP cases, leading to an EU-economic burden of ~€240 billion. These patients receive conservative treatment (e.g. pain relief medication and physiotherapy). When the latter is unsatisfactory, the only option left are invasive and costly surgical intervention. To date, no treatments halt or reverse IDD. Despite the profound socioeconomic burden and impact of IDD, decreasing the quality of life of millions of people, a game-changing treatment strategy for IDD-induced LBP is almost non-existent. The iPSpine consortium was formed to initiate a European-led research effort to identify a future advanced therapeutic strategy that results into a radical new treatment of IDD-induced LBP. With their multi-disciplinary expertise in the development of advanced therapies and their translation from bench to bedside, the aim of the iPSpine team is to investigate and develop a new advanced therapy medicinal product (ATMP) of the future, based on a novel developmental biology-based therapeutic strategy employing pluripotent stem cells (iPSC) and smart biomaterials. The iPSpine consortium will develop and demonstrate Proof-of-concept with the aid of novel and extended knowledge, tools and technology platforms. Hereby, iPSpine has the ambition to make a significant contribution by reducing translational bottlenecks through open innovation and take European leadership in the development of ATMPs. The iPSpine impact: iPSpine seeks to offer novel technologies and ATMPs for the advanced therapy research and development community. IDD will be the showcase, offering improved quality of life for millions of patients with IDD-induced LBP, through long-lasting reduction of LBP, reduced LBP-related premature retirement, and improved socio-economic contribution.

Coordinator

UNIVERSITEIT UTRECHT

Address

Heidelberglaan 8
3584 Cs Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 522 312,50

Participants (19)

Sort alphabetically

Sort by EU Contribution

Expand all

TECHNISCHE UNIVERSITEIT EINDHOVEN

Netherlands

EU Contribution

€ 1 306 771,25

UNIVERSITE DE NANTES

France

EU Contribution

€ 1 250 312,50

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 708 710

NATIONAL UNIVERSITY OF IRELAND GALWAY

Ireland

EU Contribution

€ 671 935

UNIVERSITAET ULM

Germany

EU Contribution

€ 501 583,75

UNIVERSITAET BERN

Switzerland

EU Contribution

€ 419 000

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 826 617,50

NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 867 156,25

AO-FORSCHUNGSINSTITUT DAVOS

Switzerland

EU Contribution

€ 491 250

SHEFFIELD HALLAM UNIVERSITY

United Kingdom

EU Contribution

€ 1 126 572,50

UNIVERSITA CAMPUS BIO MEDICO DI ROMA

Italy

EU Contribution

€ 557 975

NTRANS TECHNOLOGIES BV

Netherlands

EU Contribution

€ 770 625

UNIVERSITE DE MONTPELLIER

France

EU Contribution

€ 364 903,75

UNIVERSITY OF MIAMI

United States

EU Contribution

€ 250 175

SPINESERV GMBH & CO.KG

Germany

EU Contribution

€ 321 250

THE UNIVERSITY OF HONG KONG

Hong Kong

PHARMALEX GMBH

Germany

EU Contribution

€ 676 381,25

Catalyze B.V.

Netherlands

EU Contribution

€ 251 250

STICHTING NATIONAAL REUMAFONDS

Netherlands

EU Contribution

€ 75 000

Project information

Grant agreement ID: 825925

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 15 396 031,25

  • EU contribution

    € 14 959 781,25

Coordinated by:

UNIVERSITEIT UTRECHT

Netherlands